Delving into the results from the head to head trial between orforglipron from Eli Lilly and oral semaglutide from Novo Nordisk in diabetes and obesity.

Executed on:Oct 31, 2025 9:30 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: University of California at San DiegoBoard-certified Obesity Medicine Physician and Medical Director for the Weight Management Program at UC San Diego Health
Treats over 100 patients per year with obesity with a variety of methods including surgery, medication, nutrition, behavior, and lifestyle support.
Clinical interest in metabolism, weight regulation, treatment of obesity and weight-related medical conditions; Research interests include anti-obesity medications, obesity medicine education and bariatric surgery.

Interview Goal

This call will evaluate the current standard of care and the potential of orforglipron, an oral GLP-1 being developed by Eli Lilly for the treatment of obesity/diabetes.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.